Transluminal Technologies is ready to take on the European market with CE Mark approval for its flagship Velox CD vascular closure devices.
The single-size device is novel in its category, featuring metal-based bioabsorbable materials in a design to help physicians close cuts in arterial walls during minimally invasive surgeries. The single-size Velox system can close arteriotomies ranging from 5F to 8F and the implant dissolves completely within 2 weeks, according to Transluminal Technologies.
"Velox CD is the world’s first metal-based bioabsorbable closure device that is simple to use and highly predictable for femoral access site hemostasis," Velox clinical trial leading clinical participant Dr. Shing-Chiu Wong said on behalf of the company. "This innovation should prove to be a significant enhancement to the existing offerings."
Established in 2007, Transluminal Tech. hopes to leverage its proprietary absorbable biometals into novel, minimally invasive cardiovascular devices. The company hopes to ride a wave of increasing demand for minimally invasive endovascular devices for the interventional cardiology market, which is projected to be a $12.7 billion worldwide market by 2016.